Edition:
United States

Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

31.11USD
14 Dec 2017
Change (% chg)

$0.05 (+0.16%)
Prev Close
$31.06
Open
$31.05
Day's High
$31.62
Day's Low
$31.02
Volume
14,945
Avg. Vol
20,647
52-wk High
$35.87
52-wk Low
$12.67

Chart for

About

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

China cancer specialist Chi-Med plans $262 mln share offering

LONDON, Oct 25 China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development of its pipeline.

Oct 25 2017

BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity

* Astrazeneca and Chi-med’s Savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with met-amplification

Oct 16 2017

UPDATE 1-Celgene signs deal with BeiGene for tumor cancer treatment

July 6 Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China-based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology.

Jul 06 2017

Earnings vs. Estimates